REG - AstraZeneca PLC - Transfer of rights to Eklira, Duaklir completed

AstraZenecaAnnouncement

05/01/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220105:nRSE4812Xa&default-theme=true

RNS Number : 4812X  AstraZeneca PLC  05 January 2022

5 January 2022 07:00 GMT

 

Transfer of global rights for Eklira and Duaklir to Covis Pharma completed

 

AstraZeneca has completed the transfer of its global rights to Eklira
(aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium
bromide/formoterol) to Covis Pharma Group (Covis Pharma).

 

Financial considerations

Under the terms of the agreement, AstraZeneca received a payment of $270m from
Covis Pharma. AstraZeneca will also receive payments in respect of certain
ongoing development costs related to the medicines. The income arising from
the upfront payment will be fully offset by a charge for derecognition of the
associated intangible asset and therefore no Other Operating Income will be
recognised in AstraZeneca's financial statements.

 

Notes

 

Eklira and Duaklir

Eklira (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) are
inhaled respiratory medicines used for the maintenance treatment of chronic
obstructive pulmonary disease. Eklira is a long-acting muscarinic antagonist
(LAMA), which is marketed in the US as Tudorza and in some countries as
Bretaris.

 

Duaklir is a combination therapy that contains both a LAMA and a long-acting
beta2-agonist (LABA). It is marketed in some countries as Brimica.

 

Both medicines are presented as a dry powder for inhalation and are delivered
via a breath-actuated multi-dose dry powder inhaler, Genuair (Pressair in the
US). AstraZeneca licensed the global rights to both products from Almirall
S.A. in 2014.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (https://www.astrazeneca.com/) and follow the
Company on Twitter @AstraZeneca (https://twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCBKPBBABKKNDK